GIS trade ideas
GILD nearing pullback at top of long-term channelGILD nearing pullback at the top of it's multiyear channel.
GILD Showing some positive price actionTesting the top of a long term range. May fall back but if it breaks and pushes through 200 could see a significant move up.
GILD Double White Candles Test ResistanceGilead Sciences, Inc. is testing the resistance to begin completion of this longer-term bottoming formation. The W bottom formation has tiers of resistance to overcome. Hybrid Leading Indicators show strengthening pattern.
$GILD Time to be BULLISH on Gilead Sciences.Gilead reported earnings on Thursday and it may be finally turning the corner. GILD was considered a one trick pony due to the success of its Hepatitis drugs, which unfortunately have starting to drop in revenue. That decline has been meet with a rising revenue stream from new HIV treatments, which tend to be longer term treatments than Hepatitis cases. As a result of recent acquisitions, Oncology is also a growing revenue stream with Yescarta more than doubling revenue to $96m in the first quarter. GILEAD also has a sizable cash at hand of $30 Billion along with a very strong balance sheet. Analysts have a overweight rating on the stock and a average price target of $81, we expect some upgrades in the days to come. NASDAQ:GILD
Company Description
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands.
Gilead Sciences - earnings after the bellGilead Sciences, Inc. is expected to report earnings after market close. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $1.53. The reported EPS for the same quarter last year was $1.37.
Gilead under performed the XBI - S&P Biotech ETF since Q3 2016. Horizontal support at $60.32 will be a key technical level to watch out for.
Good breakdown potential.NASDAQ:GILD Look for a bounce first at the open and short on the way down below 5day moving average 66.40. keep in mind that it's trading above a declining 5day MA. participate until it breaks below 5 day MA.
[GILD] phase 4 -> don't buyThe price fell 372 pp! The slope of 30MM is negative and we see clearly a resistance. Don't buy.
Scalper - GILD - 15m chart - Oct 19, 2018Based on my proprietary indicator (in testing mode):
Long
Entry on green arrow
Exit on red arrow or stop loss or target hit
Short
Vice versa
GILD getting attention againGILD just broke the ichi cloud and heading toward a break out point. Money has been moving back into heath/bio stocks.
Never completed the three drive of my previous post but looks strong here.
GILD: Sort opportunityAn intraday high potential, Back Tested Sort Analysis.
We ll try to enter into the correction of the uptrend movement.
DETAILS ON THE CHART
NOTE: Entry range area above the entry point, is calculated upon 80% of the recorded pullback back tested past performances
DISCLAIMER: This is a technical analysis study, not an advice or recommendation to invest money on.
GILDBroke through double bottom neckline and EMAs curling upwards convincingly. This is looking very bullish.
